Diligence memo · auto-generated · as of July 2, 2026
Accu-Break Pharmaceuticals Inc
Accu-Break Pharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Accu-Break Pharmaceuticals Inc operates in Pharmaceuticals, based in Plantation.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Accu-Break Pharmaceuticals Inc has raised $1.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $1.0M on 2013-04-24.
Most recent recorded round closed around 2015-05-29.
Valuation (modeled)modeled
Provath models Accu-Break Pharmaceuticals Inc at approximately $24M (range $280K–$268M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.08× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 11.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 24% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.